Dorothy Sebikari1, Mona Farhad2, Terry Fenton2, Maxensia Owor1, Jeffrey S A Stringer3, Min Qin2, Nahida Chakhtoura4, Benjamin H Chi3, Friday Saidi5, Neetal Nevrekar6, Avy Violari7, Tsungai Chipato8, James A McIntyre9,10, Dhayendre Moodley11, Taha E Taha12, Gerhard Theron13, Mary Glenn Fowler14. 1. Clinical Department, Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda. 2. Harvard T.H. Chan School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA. 3. Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC. 4. National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Maternal and Paediatric Infectious Diseases Branch, Bethesda, MD. 5. Department of Obstetrics and Gynaecology, University of North Carolina (UNC) Project Lilongwe, Lilongwe, Malawi. 6. Clinical Research Department, Byramiee Jeeieebhoy Government Medical College, Pune, India. 7. Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 8. Department of Obstetrics and Gynecology, University of Zimbabwe, Harare, Zimbabwe. 9. Anova Health Institute, Johannesburg, South Africa. 10. Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, South Africa. 11. Department of Obstetrics and Gynecology, School of Clinical Medicine, Centre for AIDS Research in South Africa, University of KwaZulu Natal, Durban, South Africa. 12. Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD. 13. Department of Obstetrics and Gynecology, Stellenbosch University, Cape Town, South Africa. 14. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
BACKGROUND: In the multicountry PROMISE 1077BF/1077FF trial, the risk of low birth weight (LBW; <2500 g) and preterm delivery (PTD; <37 weeks) was significantly higher among women initiating a protease inhibitor-based antiretroviral treatment (ART) regimen than those receiving ZDV alone. Among those assigned to a protease inhibitor regimen, tenofovir/emtricitabine was associated with the more severe outcomes of very LBW (<1500 g) and very PTD (<34 weeks) compared with zidovudine/lamivudine. METHODS: We used multivariate logistic regression to further explore these treatment findings, taking into account demographic baseline clinical and postentry obstetrical factors. We evaluated individual adverse outcomes and composites that included stillbirth and early loss/spontaneous abortion. RESULTS: Among 3333 women delivering at least 1 live infant, median maternal age at enrollment was 26 years; 661 (20%) were primiparous, and 110 (3.3%) reported at least 1 previous PTD. Seventeen percent of newborns were LBW, 1% were very LBW, 17% had PTD, and 3% had very PTD. Treatment allocation remained strongly associated with multiple adverse outcomes after controlling for other risk factors with both ART regimens exhibiting increased risk relative to ZDV alone. Other risk factors remaining significant in at least one of the multivariate models included the following: country, gestational age at entry, maternal age, maternal body mass index, previous PTD, history of alcohol use, baseline HIV viral titer, multiple gestation, and several obstetric risk factors. CONCLUSIONS: ART effects on adverse pregnancy outcomes reported in the randomized PROMISE trial remained strongly significant even after controlling for demographic, baseline clinical, and obstetrical risk factors, which were also associated with these outcomes.
RCT Entities:
BACKGROUND: In the multicountry PROMISE 1077BF/1077FF trial, the risk of low birth weight (LBW; <2500 g) and preterm delivery (PTD; <37 weeks) was significantly higher among women initiating a protease inhibitor-based antiretroviral treatment (ART) regimen than those receiving ZDV alone. Among those assigned to a protease inhibitor regimen, tenofovir/emtricitabine was associated with the more severe outcomes of very LBW (<1500 g) and very PTD (<34 weeks) compared with zidovudine/lamivudine. METHODS: We used multivariate logistic regression to further explore these treatment findings, taking into account demographic baseline clinical and postentry obstetrical factors. We evaluated individual adverse outcomes and composites that included stillbirth and early loss/spontaneous abortion. RESULTS: Among 3333 women delivering at least 1 live infant, median maternal age at enrollment was 26 years; 661 (20%) were primiparous, and 110 (3.3%) reported at least 1 previous PTD. Seventeen percent of newborns were LBW, 1% were very LBW, 17% had PTD, and 3% had very PTD. Treatment allocation remained strongly associated with multiple adverse outcomes after controlling for other risk factors with both ART regimens exhibiting increased risk relative to ZDV alone. Other risk factors remaining significant in at least one of the multivariate models included the following: country, gestational age at entry, maternal age, maternal body mass index, previous PTD, history of alcohol use, baseline HIV viral titer, multiple gestation, and several obstetric risk factors. CONCLUSIONS:ART effects on adverse pregnancy outcomes reported in the randomized PROMISE trial remained strongly significant even after controlling for demographic, baseline clinical, and obstetrical risk factors, which were also associated with these outcomes.
Authors: Kathleen M Powis; Douglas Kitch; Anthony Ogwu; Michael D Hughes; Shahin Lockman; Jean Leidner; Erik van Widenfelt; Claire Moffat; Sikhulile Moyo; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Infect Dis Date: 2011-08-15 Impact factor: 5.226
Authors: Françoise Renaud; Lynne M Mofenson; Charlotte Bakker; Helen Dolk; Valeriane Leroy; Angelina Namiba; Leyla Sahin; Roger Shapiro; Amy Slogrove; Claire Thorne; Marissa Vicari; Daniel Low-Beer; Meg Doherty Journal: J Int AIDS Soc Date: 2022-07 Impact factor: 6.707
Authors: Maria de Lourdes Benamor Teixeira; Trevon L Fuller; Maria Isabel Fragoso Da Silveira Gouvêa; Maria Letícia Santos Cruz; Loredana Ceci; Fellipe Pinheiro Lattanzi; Leon Claude Sidi; Wallace Mendes-Silva; Karin Nielsen-Saines; Esau Custodio Joao Journal: Antimicrob Agents Chemother Date: 2020-11-17 Impact factor: 5.191
Authors: Kim Anderson; Emma Kalk; Hlengiwe P Madlala; Dorothy C Nyemba; Nisha Jacob; Amy Slogrove; Mariette Smith; Max Kroon; Michael C Harrison; Brian S Eley; Andrew Boulle; Landon Myer; Mary-Ann Davies Journal: AIDS Date: 2021-05-01 Impact factor: 4.632
Authors: Nicole Salazar-Austin; Silvia Cohn; Sanjay Lala; Ziyaad Waja; Kelly E Dooley; Christopher J Hoffmann; Richard E Chaisson; Neil Martinson Journal: Clin Infect Dis Date: 2020-09-12 Impact factor: 9.079